Glen Chertow on MBD and clinical practice.
Starts with the high mortality of CVD in ESRD slide shown at every gatheriong of nephrologists.
MBD as a non-traditional risk factor for CVD
HEMO, 4D, Wrone on homocysteine, D-COR all RCT, All negative. [should add correction of anemia study]
45% drop out in D-COR lead to a loss of power and contributed to negative trial.
Cinacalcet approved based on its ability to get the PTH down and get patient to guidelines but we are missing the information on whether this helps patients.
Power is the probablity of detecting the treatment affect if it really exists. 90% power means that 9 out of 10 times you will detect a treatment effect if it exists.
With 3883 patients EVOLVE had 88% power to detect 20% reduction in cardiovascular disease. If the benefit is 15%, which would phenomenally important to our patients, we may not be able to detect it.